Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bactiguard Holding AB ( ($SE:BACTI.B) ) just unveiled an update.
Bactiguard reported first-quarter 2026 revenue of SEK 46.9 million, down 25% year on year, with net sales falling 28% and an operating loss widening to SEK 7.2 million, pressured by significant negative currency effects. Despite lower volumes, the company maintained positive adjusted EBITDA of SEK 4.9 million through a disciplined cost base and highlighted the resilience of its scalable license-based business model.
Partnerships with BD and Zimmer Biomet remained central to the strategy, with Bactiguard-coated products starting to sell in parts of Europe and work advancing on MDR transition and post-market clinical studies for trauma implants. The wound management segment delivered SEK 18.2 million in revenue excluding currency effects, and Bactiguard invested further in regulatory pathways, including U.S. FDA-related work, while strengthening its leadership team in communications, business development, regulatory, quality, and wound management to support long-term growth.
More about Bactiguard Holding AB
Bactiguard Holding AB is a Swedish medical technology company focused on infection prevention solutions for healthcare. Its primary products and technologies include antimicrobial coatings for medical devices, such as catheters and trauma implants, and a wound management portfolio led by Hydrocyn aqua, with a market focus on Europe and other international markets through global partnerships.
Average Trading Volume: 9,952
Technical Sentiment Signal: Sell
Current Market Cap: SEK618.5M
For detailed information about BACTI.B stock, go to TipRanks’ Stock Analysis page.